Layoffs are always big news in pharma, as they are seen as an indicator of
the health of the industry. Companies don't like to have to announce them, but
when they decide to, getting plenty of attention becomes important. That is to
impress upon investors that their CEOs are making the hard decisions needed to
keep costs in line. Of course employees are interested. They know from the
inside what is about to happen, and having lived through the awful
anticipation, they want to see what the carnage is really going to be.
The patent cliff is often the big culprit. One might think that a
one-to-one relationship could be graphed between what is happening with the
patent cliff and layoffs, but that is not the case. Pharma analysis company
EvaluatePharma has forecast that there